Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis
Background: X-linked hypophosphatemia (XLH) is a rare, progressive disorder characterized by excess fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D synthesis. Burosumab is a recombinant human monoclonal antibody that inhibits FGF23, restoring patien...
Saved in:
Main Authors: | Annemieke M. Boot (Author), Gema Ariceta (Author), Signe Sparre Beck-Nielsen (Author), Maria Luisa Brandi (Author), Karine Briot (Author), Carmen de Lucas Collantes (Author), Sandro Giannini (Author), Dieter Haffner (Author), Richard Keen (Author), Elena Levtchenko (Author), M. Zulf Mughal (Author), Outi Mӓkitie (Author), Ola Nilsson (Author), Dirk Schnabel (Author), Liana Tripto-Shkolnik (Author), M. Carola Zillikens (Author), Jonathan Liu (Author), Alina Tudor (Author), Francesco Emma (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
by: Maria Luisa Brandi, et al.
Published: (2022) -
Impact of burosumab on lower limb alignment in children with X-linked hypophosphatemia
by: David B. Frumberg, MD, FAAOS, et al.
Published: (2024) -
Burosumab - new potent treatment for X-linked hypophosphatemia and tumor-induced osteomalacia
by: Magda Wojtuś, et al.
Published: (2023) -
Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
by: Silvia Martín Ramos, et al.
Published: (2020) -
Dental health of patients with X-linked hypophosphatemia: A controlled study
by: Amila Larsson, et al.
Published: (2023)